Promising Results: Acumen Pharmaceuticals’ Experimental Alzheimer’s Drug Passes Initial Safety Test
Acumen Pharmaceuticals said that an experimental Alzheimer’s drug developed by the company has passed an initial safety test, and will move to larger trials. The drug targets a new form of the toxic beta-amyloid protein in the brain. The company said the drug, ACI-193, was well received in its first trial in patients. The company … Read more